With median progression-free survival reaching seven years in first-line follicular lymphoma patients, evaluating new treatments is difficult. Daniel Sargent, PhD, describes an easier-to-assess, accurate endpoint.
David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma
